Oral Oncolytics Will Require Health Care System to Adapt
Judging from the drug pipeline, the future of oncology is oral chemotherapy.
Judging from the drug pipeline, the future of oncology is oral chemotherapy.
BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.
PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.
Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.
The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.
Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.
FF-10832—an investigational liposomal formulation of gemcitabine—has received orphan drug designation from the FDA for biliary tract cancer.
Panelists discuss how identifying appropriate candidates for allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute myeloid leukemia (AML) involves evaluating remission status, relapse risk based…
Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.